Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes
NCT06706284
Recruiting
It is not known whether a new diabetes drug, semaglutide, is an effective treatment for type 2 diabetes for persons with spinal cord injury (SCI), a population at higher risk for this condition. Therefore, this study looks at the effect of semaglutide on glucose levels in the body and other information about type 2 diabetes and obesity.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/15/2025
Locations: University Health - Texas Diabetic Institute, San Antonio, Texas +1 locations
Conditions: Spinal Cord Injuries, Type 2 Diabetes
Register for Updates
Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range
NCT05564117
Completed
This study will look how well semaglutide tablets taken once daily helps people with body weight above the healthy range. Participants will either get semaglutide 25 milligram (mg) once daily or placebo once daily. This study will last for 72 weeks, which includes 1-week screening period, 64 weeks of treatment period and 7 weeks of follow up period.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: Univsty Of AL At Birmingham, Birmingham, Alabama +21 locations
Conditions: Overweight, Obesity
Register for Updates
Early Re-Initiation of Semaglutide Post Sleeve Gastrectomy in Youth
NCT06934655
Not Yet Recruiting
This is a Phase 3a, randomized, parallel-controlled trial designed to compare the early re-initiation of semaglutide, starting two weeks after sleeve gastrectomy, to standard care (no pharmacotherapy following surgery). The trial will involve 150 youth with severe obesity who have been on semaglutide 2.4 mg weekly for at least 3 months prior to surgery. Participants will be randomized to either (1) semaglutide 2.4 mg weekly or (2) standard care for 24 months. Primary, secondary, and tertiary out... Read More
Gender:
ALL
Ages:
Between 12 years and 18 years
Trial Updated:
04/11/2025
Locations: Children's Hospital Los Angeles, Los Angeles, California
Conditions: Pediatric Obesity, Metabolic and Bariatric Surgery, Semaglutide
Register for Updates
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
NCT05371496
Enrolling By Invitation
The purpose of this research is to find out if an aggressive intervention to lose weight, will improve symptoms in patients with obesity-related cardiomyopathy, which is also known as the obese phenotype of heart failure with preserved ejection fraction (HFpEF).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/01/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Cardiomyopathy, Heart Failure With Preserved Ejection Fraction (HFpEF), Obesity
Register for Updates
Triple Therapy in T1DM
NCT03899402
Active Not Recruiting
To assess whether the addition of dapagliflozin to semaglutide and insulin (triple therapy) improves glycemic control in patients with type 1 diabetes compared with semaglutide and insulin (dual therapy) and insulin only (standard) treatment.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/31/2025
Locations: Diabetes and Endocrinology Research Center of WNY, Williamsville, New York
Conditions: Type 1 Diabetes Mellitus
Register for Updates
Semaglutide for Alcohol Use Disorder
NCT05520775
Completed
This is an early-Phase II human laboratory trial using a randomized, placebo-controlled, dose-ranging design to investigate the effects of semaglutide, a GLP-1 receptor agonist, on alcohol-related outcomes in adults with alcohol use disorder (AUD).
Gender:
ALL
Ages:
Between 21 years and 65 years
Trial Updated:
03/25/2025
Locations: UNC-Chapel Hill, Chapel Hill, North Carolina
Conditions: Alcohol Use Disorder, Cigarette Smoking
Register for Updates
Semaglutide Treatment, Appetite, and Eating Behavior: Long-term Effects
NCT05548647
Active Not Recruiting
This study will evaluate the effect of semaglutide on eating behavior, appetite (hunger/fullness), and food liking in the long-term, as compared to placebo. All participants will receive lifestyle modification (diet and exercise) counseling, and will be prescribed the FDA-approved weight loss medication, semaglutide, or placebo (an inactive saline solution) for 72 weeks.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/24/2025
Locations: University of Pennsylvania Center for Weight and Eating Disorders, Philadelphia, Pennsylvania
Conditions: Obesity
Register for Updates
Semaglutide Therapy for Alcohol Reduction - Tulsa
NCT05891587
Recruiting
The purpose of this research study is to determine if semaglutide, when compared to placebo, is safe and may reduce alcohol drinking in individuals who endorse symptoms consistent with alcohol use disorder.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: OSU Biomedical Imaging Center, Tulsa, Oklahoma
Conditions: Alcohol Use Disorder
Register for Updates
Comparing Semaglutide Versus Placebo on Intestinal Barrier Function in Type 2 Diabetes Mellitus (SIB)
NCT04979130
Completed
This study plans to learn more about the effect of semaglutide once weekly on intestinal permeability in individuals with type 2 diabetes.
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
03/17/2025
Locations: University of Colorado Anschutz, Aurora, Colorado
Conditions: Type 2 Diabetes, Chronic Inflammation, Intestinal Permeability
Register for Updates
Feasibility of Semaglutide in Advanced Lung Disease
NCT05746039
Recruiting
The goal of this clinical trial is to learn whether semaglutide, an FDA-approved treatment for diabetes and obesity, is feasible and tolerable in patients with advanced lung disease. The main question\[s\] it aims to answer are: 1. Are patients with advanced lung disease able to tolerate semaglutide therapy? 2. Are we able to titrate semaglutide therapy to a target weight? Participants will be asked to perform pulmonary function, physical function and body composition testing, as well as a bl... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
03/13/2025
Locations: University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania
Conditions: Obesity, Interstitial Lung Disease, Chronic Obstructive Pulmonary Disease, Sarcoidosis, Pulmonary, Pulmonary Hypertension
Register for Updates
A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease
NCT03819153
Completed
The researchers are doing this study to see if semaglutide can slow down the growth and worsening of chronic kidney disease in people with type 2 diabetes. Participants will get semaglutide (active medicine) or placebo ('dummy medicine'). This is known as participants' study medicine - which treatment participants get is decided by chance. Semaglutide is a medicine, doctors can prescribe in some countries for the treatment of type 2 diabetes. Participants will get the study medicine in a pen. Pa... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/13/2025
Locations: Dr. Terence Hart, Tuscumbia, Alabama +412 locations
Conditions: Diabetes Mellitus, Type 2
Register for Updates
Research Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 Diabetes
NCT04707469
Completed
This study compares three doses of once daily semaglutide tablets in people with type 2 diabetes who were previously treated with other oral anti-diabetic medicines. Participants will be initiated on the lowest starting dose of 3 mg and gradually increased until they reach the final trial dose of 14 mg, 25 mg or 50 mg once daily semaglutide tablets. The final three doses will be randomized (i.e., decided by chance). Participants will be administered one tablet per day for 68 weeks. Women cannot... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: American Clinical Trials, Buena Park, California +180 locations
Conditions: Diabetes Mellitus, Type 2
Register for Updates